MX2021002051A - Imidazo[1,2-b]piridaziinas como inhibidores de trk. - Google Patents
Imidazo[1,2-b]piridaziinas como inhibidores de trk.Info
- Publication number
- MX2021002051A MX2021002051A MX2021002051A MX2021002051A MX2021002051A MX 2021002051 A MX2021002051 A MX 2021002051A MX 2021002051 A MX2021002051 A MX 2021002051A MX 2021002051 A MX2021002051 A MX 2021002051A MX 2021002051 A MX2021002051 A MX 2021002051A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- compounds
- imidazo
- pyridazines
- relates
- Prior art date
Links
- 150000004942 imidazo[1,2-b]pyridazines Chemical class 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 5
- 150000003839 salts Chemical class 0.000 abstract 3
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 102000005937 Tropomyosin Human genes 0.000 abstract 1
- 108010030743 Tropomyosin Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a ciertos compuestos de imidazo[1,2-b]piridazina y las sales farmacéuticamente aceptables de dichos compuestos. La invención también se refiere a los procesos para la preparación de los compuestos, las composiciones que contienen los compuestos, y los usos de dichos compuestos y sales en el tratamiento de enfermedades o afecciones asociadas con la actividad de la cinasa relacionada con la tropomiosina ("Trk", por sus siglas en inglés). Más específicamente, la invención se refiere a los compuestos y sus sales útiles como inhibidores de Trk. (ver Fórmula) en donde, R1, R2, R3, R4 y R5, L y Z son tal como se definen en la presente.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1813791.9A GB201813791D0 (en) | 2018-08-23 | 2018-08-23 | Organic compounds |
| PCT/GB2019/052378 WO2020039209A1 (en) | 2018-08-23 | 2019-08-23 | Imidazo[1,2-b]pyridazines as trk inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021002051A true MX2021002051A (es) | 2021-06-23 |
Family
ID=63715095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021002051A MX2021002051A (es) | 2018-08-23 | 2019-08-23 | Imidazo[1,2-b]piridaziinas como inhibidores de trk. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20210253572A1 (es) |
| EP (1) | EP3840832B1 (es) |
| JP (1) | JP7417594B2 (es) |
| KR (1) | KR20210049089A (es) |
| CN (1) | CN112805062B (es) |
| AU (1) | AU2019325375A1 (es) |
| BR (1) | BR112021003026A2 (es) |
| CA (1) | CA3106431A1 (es) |
| DK (1) | DK3840832T3 (es) |
| EA (1) | EA202190323A1 (es) |
| ES (1) | ES2968695T3 (es) |
| FI (1) | FI3840832T3 (es) |
| GB (1) | GB201813791D0 (es) |
| IL (1) | IL280513B1 (es) |
| MA (1) | MA53432A (es) |
| MX (1) | MX2021002051A (es) |
| PL (1) | PL3840832T3 (es) |
| PT (1) | PT3840832T (es) |
| SG (1) | SG11202100338PA (es) |
| WO (1) | WO2020039209A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023511170A (ja) * | 2020-01-22 | 2023-03-16 | ベネボレントエーアイ バイオ リミティド | 医薬組成物及びその使用 |
| EP4093376A1 (en) * | 2020-01-22 | 2022-11-30 | BenevolentAI Bio Limited | Pharmaceutical compositions and their uses |
| CN112979646B (zh) * | 2021-03-08 | 2022-01-14 | 北京富龙康泰生物技术有限公司 | 一种咪唑并吡啶类衍生物 |
| WO2022234287A1 (en) | 2021-05-06 | 2022-11-10 | Benevolentai Bio Limited | Imidazopyridazine derivatives useful as trk inhibitors |
| CN113444070A (zh) * | 2021-07-28 | 2021-09-28 | 深圳市真味生物科技有限公司 | 一种由手性叔丁基亚磺酰胺合成手性尼古丁的制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
| JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
| GB0405937D0 (en) | 2004-03-16 | 2004-04-21 | Glaxo Group Ltd | Compounds |
| GB0412467D0 (en) | 2004-06-04 | 2004-07-07 | Astrazeneca Ab | Chemical compounds |
| UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
| CN108329246B (zh) | 2011-05-13 | 2021-02-26 | 阵列生物制药公司 | 作为trka激酶抑制剂的吡咯烷基脲和吡咯烷基硫脲化合物 |
| BR112014014276A2 (pt) | 2011-12-12 | 2017-06-13 | Dr Reddys Laboratories Ltd | composto, composição farmacêutica, método para inibir uma cinase receptora, e, métodos para tratar condições, doenças e/ou distúrbios, e dor |
| JP6160613B2 (ja) | 2012-04-26 | 2017-07-12 | 小野薬品工業株式会社 | Ｔｒｋ阻害化合物 |
| WO2014175370A1 (ja) | 2013-04-25 | 2014-10-30 | 塩野義製薬株式会社 | ピロリジン誘導体およびそれらを含有する医薬組成物 |
| JP7321183B2 (ja) | 2017-12-15 | 2023-08-04 | ピラミッド バイオサイエンシズ インコーポレイテッド | がんを治療するためのｔｒｋキナーゼ阻害物質としての、５－（２－（２，５－ジフルオロフェニル）ピロリジン－１－イル）－３－（１ｈ－ピラゾール－１－イル）ピラゾロ［１，５－ａ］ピリミジン誘導体及び関連する化合物 |
| GB201811825D0 (en) * | 2018-07-19 | 2018-09-05 | Benevolentai Bio Ltd | Organic compounds |
-
2018
- 2018-08-23 GB GBGB1813791.9A patent/GB201813791D0/en not_active Ceased
-
2019
- 2019-08-23 EP EP19759716.4A patent/EP3840832B1/en active Active
- 2019-08-23 WO PCT/GB2019/052378 patent/WO2020039209A1/en active Application Filing
- 2019-08-23 JP JP2021510134A patent/JP7417594B2/ja active Active
- 2019-08-23 SG SG11202100338PA patent/SG11202100338PA/en unknown
- 2019-08-23 US US17/270,397 patent/US20210253572A1/en active Pending
- 2019-08-23 BR BR112021003026-3A patent/BR112021003026A2/pt unknown
- 2019-08-23 PL PL19759716.4T patent/PL3840832T3/pl unknown
- 2019-08-23 MX MX2021002051A patent/MX2021002051A/es unknown
- 2019-08-23 AU AU2019325375A patent/AU2019325375A1/en active Pending
- 2019-08-23 MA MA053432A patent/MA53432A/fr unknown
- 2019-08-23 ES ES19759716T patent/ES2968695T3/es active Active
- 2019-08-23 KR KR1020217003626A patent/KR20210049089A/ko unknown
- 2019-08-23 CN CN201980054678.9A patent/CN112805062B/zh active Active
- 2019-08-23 FI FIEP19759716.4T patent/FI3840832T3/fi active
- 2019-08-23 PT PT197597164T patent/PT3840832T/pt unknown
- 2019-08-23 CA CA3106431A patent/CA3106431A1/en active Pending
- 2019-08-23 DK DK19759716.4T patent/DK3840832T3/da active
- 2019-08-23 EA EA202190323A patent/EA202190323A1/ru unknown
-
2021
- 2021-01-29 IL IL280513A patent/IL280513B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL280513B1 (en) | 2024-07-01 |
| JP2021535125A (ja) | 2021-12-16 |
| ES2968695T3 (es) | 2024-05-13 |
| PL3840832T3 (pl) | 2024-03-25 |
| FI3840832T3 (fi) | 2024-01-12 |
| WO2020039209A1 (en) | 2020-02-27 |
| KR20210049089A (ko) | 2021-05-04 |
| EP3840832B1 (en) | 2023-10-11 |
| CN112805062B (zh) | 2024-06-04 |
| CA3106431A1 (en) | 2020-02-27 |
| DK3840832T3 (da) | 2024-01-15 |
| CN112805062A (zh) | 2021-05-14 |
| BR112021003026A2 (pt) | 2021-05-11 |
| JP7417594B2 (ja) | 2024-01-18 |
| IL280513A (en) | 2021-03-01 |
| SG11202100338PA (en) | 2021-03-30 |
| GB201813791D0 (en) | 2018-10-10 |
| PT3840832T (pt) | 2024-01-15 |
| MA53432A (fr) | 2021-06-30 |
| US20210253572A1 (en) | 2021-08-19 |
| AU2019325375A1 (en) | 2021-02-04 |
| EP3840832A1 (en) | 2021-06-30 |
| EA202190323A1 (ru) | 2021-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021002051A (es) | Imidazo[1,2-b]piridaziinas como inhibidores de trk. | |
| NZ744349A (en) | Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors | |
| NZ766835A (en) | Pharmaceutical compounds | |
| TN2019000107A1 (en) | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors | |
| EA201290244A1 (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1,2-b]ПИРИДАЗИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE10 | |
| TN2019000110A1 (en) | Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors | |
| MX2021001952A (es) | Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met. | |
| EP4104837A3 (en) | Heterocyclic compounds as ret kinase inhibitors | |
| CR20210251A (es) | Derivados de 2,3-dihidro-1h-pirrolo(3,4-c)piridin-1-ona como inhibidores de hpk1 para el tratamiento del cáncer | |
| UA106054C2 (uk) | ЗАМІЩЕНІ ПІРАЗОЛО[1,5-a]ПІРИМІДИНОВІ СПОЛУКИ ЯК ІНГІБІТОРИ TРK-КІНАЗИ | |
| NZ630719A (en) | Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof | |
| MY193511A (en) | [1,2,4]triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors | |
| MY200629A (en) | Pyrazolo and triazolo bicyclic compounds as jak kinase inhibitors | |
| MX370390B (es) | Compuesto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]pirazolo[1, 5-a]pirimidin-3-carboxamida util como inhibidor de cinasa de ataxia telangiectasia mutada (atm) y rad3 relacionados (atr), su preparacion, diferentes formas solidas y sus derivados radiomarcados. | |
| GEP20156417B (en) | Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases | |
| GEP20156285B (en) | Compounds and compositions as trk inhibitors | |
| MX2010006748A (es) | Pirazolo[1,5-a]pirimidinas utiles como inhibidores de jak2. | |
| MX2022008103A (es) | Formulaciones de inhibidores de la cinasa amorfa y metodos de estas. | |
| MX2020009586A (es) | Compuestos de (2-azabiciclo[3.1.0]hexan-2-il)pirazolo[1,5-a]pirimi dina e imidazo[1,2-b]piridazina sustituidos como inhibidores de cinasas trk. | |
| NZ754944A (en) | Imidazo [1,5-a] pyrazine derivatives as pi3kdelta inhibitors | |
| MX2022006086A (es) | Derivados de piridopirimidinona como antagonistas de ahr. | |
| NZ761680A (en) | Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors | |
| MX362197B (es) | Derivados de imidazo[1,2-b]piridazina e imidazo[1,2-a]pirazina como inhibidores de la fosfodiesterasa 10; y el uso de los mismos en el tratamiento de trastornos neurológicos, psiquiátricos y metabólicos. | |
| PH12018502411A1 (en) | Novel 5h-pyrrolo[2,3-d]pyrimidin-6(7h)-one derivative | |
| MX2021000683A (es) | Derivados de imidazo[1,2-b]piridazina como inhibidores de trk. |